Detalles de la búsqueda
1.
Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2.
Br J Haematol
; 204(5): 1780-1789, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38369805
2.
A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.
Hematol Oncol
; 41(4): 704-717, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37186314
3.
miR-582-5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit proliferation and induce apoptosis of leukemia cells.
Cell Biol Int
; 44(10): 2021-2030, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32543749
4.
High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma.
Acta Haematol
; 143(3): 279-288, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31597158
5.
Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma.
Clin Proteomics
; 16: 17, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31043929
6.
Expression profile analysis of long non-coding RNA in acute myeloid leukemia by microarray and bioinformatics.
Cancer Sci
; 109(2): 340-353, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29220122
7.
Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
Hematology
; 28(1): 2265206, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37796109
8.
Protocadherin-1 serves as a prognostic biomarker and promotes pancreatic cancer progression by suppressing CD8+ T cell infiltration through CCL5-CCR5 axis.
Am J Cancer Res
; 13(11): 5197-5217, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38058826
9.
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.
J Med Case Rep
; 16(1): 459, 2022 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36496425
10.
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).
J Hematol Oncol
; 15(1): 86, 2022 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35794616
11.
Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.
J Immunother
; 44(4): 141-150, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33596023
12.
CD138- multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient.
Aging (Albany NY)
; 12(22): 23067-23081, 2020 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33197893
13.
Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma.
Cell Stress Chaperones
; 25(2): 357-367, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32026316
14.
Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens.
Hematology
; 24(1): 387-391, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30890040
15.
Management of cytokine release syndrome related to CAR-T cell therapy.
Front Med
; 13(5): 610-617, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31571160
16.
Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma.
Life Sci
; 196: 133-142, 2018 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29459023
17.
Granulocyte colony stimulating factor priming chemotherapy is more effective than standard chemotherapy as salvage therapy in relapsed acute myeloid leukemia.
Med Clin (Barc)
; 151(9): 339-344, 2018 11 09.
Artículo
en Inglés, Español
| MEDLINE | ID: mdl-29292108
18.
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
J Hematol Oncol
; 11(1): 141, 2018 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30572922
19.
[Screening of Serum Peptidome-Based Biomarker for Multiple Myeloma Renal Impairment].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 25(5): 1466-1470, 2017 Oct.
Artículo
en Zh
| MEDLINE | ID: mdl-29070126
20.
Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study.
Onco Targets Ther
; 9: 3661-9, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27382304